GB9: Activation of Brown Adipose Tissue Metabolism Using Mirabegron
Study Details
Study Description
Brief Summary
Could sympathomimetics and sympatholytics drugs safe for the management of Type 2 Diabetes (T2D)? Based on recent evidence, we propose that pharmacological stimulation of Beta-3 adrenergic receptor (ADBR3) at higher doses of Mirabegron may be required to elicit changes in glycemia, but should be combined with Beta-1 adrenergic receptor (ADRB1) antagonists to suppress the unwanted effects on the cardiovascular system.
Together, several results establish a previously unappreciated cross-talk between Gs-coupled ADRB1 and ADRB3 in adipose tissue for the control of glucose homeostasis. Moreover, these data suggest that antagonizing ADRB1 may be a good way to significantly lower the dose of ADRB3 agonist required for glucose control.
Therefore, we believe that there are therapeutic opportunities in targeting adrenergic receptors for the treatment of T2D at least in young/middle aged people.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In brief, participants will take part in 2 metabolic studies (A and B) performed in random order and at an interval of 7 to 14 days. Each metabolic study will last 8.5 hours with a baseline period of 2.5 hours. Participants will ingest either 200 mg of the ADRB3 agonist mirabegron (Myrbetriq, Astellas Pharma Canada) alone (study A) or in combination with 10 mg of bisoprolol, an ADRB1-antagonist (study B), at time 0.
The radioactive PET tracers (PET: positron emission tomography) used in this study are the [11C]-acetate and [18F]-FDG to estimate BAT oxidative metabolism and glucose metabolism, respectively. The perfusion of [6,6 D2]-glucose, [1,1,2,3,3-2H]-glycerol and [U-13C]-palmitate stable isotopes will also be performed in this study from time -150 min. to +300 min to examine the systemic appearance rate of glucose, glycerol and fatty acids, respectively. These studies will be almost identical (same perfusion of stable and radioactive tracers, same number of PET acquisitions) except for the drug which will be administered orally at time 0.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Study A Metabolic PET study with mirabegron |
Drug: Mirabegron
Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Other Names:
|
| Experimental: Study B Metabolic PET study with mirabegron and bisoprolol |
Drug: Mirabegron
Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Other Names:
Drug: Bisoprolol Fumarate
a single dose of 10 mg (2 tablets of 5 mg)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in activation of Brown Adipose Tissue (BAT) (oxidative metabolism and blood flow) [30 minutes before and 210 minutes after drug administration]
Measured with 11C-acetate using dynamic PET/CT acquisition.
- BAT glucose uptake [240 minutes after drug administration]
Assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning
Secondary Outcome Measures
- Whole-body glucose partitioning [300 minutes after drug administration]
Assessed using i.v. injection of 18FDG with static PET/CT scanning
- Whole-body lipolysis [150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).]
Systemic appearance rate of glycerol and fatty acid determined by perfusion of [1,1,2,3,3-2H]-glycerol, [U-13C]-palmitate tracers. and concentration of total NEFA, triglycerides, palmitate, oleate, linoleate, glycerol.
- Hepatic Glucose production [150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).]
Systemic appearance rate of glucose determined by perfusion of [6,6 D2]-glucose
- Substrate utilisation [150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state).]
VO2 and VCO2 will be measured by indirect calorimetry to calculate carbohydrate and fatty acid oxidation rates.
- BAT lipolysis [baseline and 300 minutes after drug administration]
Estimated by quantifying changes in tissue radiodensity with CT.
- Changes in pancreatic and gut hormones [150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).]
measured with ELISA and Milliplex.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy subjects with normal glucose tolerance determined according to an oral glucose tolerance test;
-
BMI ≤ 30 kg/m2.
Exclusion Criteria:
-
Plasma triglycerides > 5.0 mmol/L at fasting;
-
More than 2 alcohol consumption per day;
-
More than 1 cigarette per day;
-
History of total cholesterol level > 7 mmol/L, of cardiovascular disease, hypertensive crisis;
-
Treatment with fibrates, thiazolidinedione, insulin,betablockers or other drugs with effects on insulin resistance or lipid metabolism (exception for antihypertensive drugs, statins or metformin);
-
Presence of a noncontrolled thyroid disease, renal or hepatic disease, history of pancreatitis, bleeding diatheses, cardiovascular disease or any other serious medical conditions;
-
History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux having required a surgery, etc.); reflux having required a surgery, etc.);
-
Presence of a pacemaker;
-
Have undergone of PET study or CT scan in the past year;
-
Chronic administration of any medication;
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre de recherche du CHUS | Sherbrooke | Quebec | Canada | J1H 5N4 |
Sponsors and Collaborators
- Université de Sherbrooke
- Laval University
Investigators
- Principal Investigator: Denis Blondin, Université de Sherbrooke
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-3791